Pharmaceutical Serialization Further Expands Foil Specification
Pharmaceutical brands increasingly specify diversified-manufacturer foil and lidding previously limited to simple rigid-can lines, applying it across an expanding list of serialized blister formats as regulatory expansion increasingly makes documented barrier certification a measurable production-capacity consideration rather than a manageable compliance detail. This shift is creating substantial new demand beyond the category's traditional rigid base, giving diversified manufacturers a genuine growth avenue tied to pharmaceutical expansion rather than pure rigid-can volume growth. Manufacturers with established pharmaceutical brand relationships are capturing disproportionate share of this expanding demand across newly converted accounts worldwide.
Market Impact: Sustains 24% of rigid-can volume








